McKesson Corporation(MCK)

New York Stock Exchange
Sector: Healthcare | Industry: Medical - Distribution
McKesson Corporation logo

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The International segment offers distribution and services to wholesale, institutional, and retail customers in 13 European countries and Canada. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers. The RxTS segment serves biopharma and life sciences partners and patients to address medication challenges for patients throughout their journeys; connects pharmacies, providers, payers, and biopharma companies to deliver innovative access and adherence solutions; and provides third-party logistics and wholesale distribution support solutions. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.

Latest News & Analysis

McKesson expands into ophthalmology with PRISM Vision Holdings acquisition, impacting MCK stock and EPS. Analysis of market trends, financial performance, and strategic rationale.
Apr 4, 2025

McKesson's (MCK) PRISM Acquisition: Strategic Financial Impact

McKesson's acquisition of PRISM Vision Holdings strategically expands into ophthalmology, promising EPS growth and market leadership amidst evolving healthcare dynamics.

Read more →
McKesson (MCK) stock analysis: defensive strategy, GLP-1 growth, PRISM Vision acquisition, and dividend potential for investors.
Apr 2, 2025

McKesson (MCK): Analyst Optimism, GLP-1 Growth, and Defensive Stock Strategy

McKesson (MCK) navigates market volatility with analyst optimism, driven by GLP-1 growth and strategic acquisitions. A defensive stock with dividend growth potential.

Read more →
McKesson Corporation: Navigating growth amidst economic headwinds, strategic acquisitions, and the GLP-1 drug boom.
Mar 25, 2025

McKesson (MCK): GLP-1 Growth, Strategic Acquisitions & Challenges

McKesson navigates healthcare's complexities with strategic acquisitions and GLP-1 demand, balancing growth with financial stability amid regulatory and economic challenges.

Read more →
McKesson (MCK) Q3 2025 Earnings Analysis: Revenue Growth, Profitability Pressures, and Strategic Acquisitions
Mar 14, 2025

McKesson (MCK) Q3 2025 Earnings: Challenges and Growth Ahead

McKesson's Q3 2025 earnings reveal strategic shifts amid challenges like gross margin contraction and declining COVID-related sales. A deep dive into MCK's resilience and growth prospects.

Read more →
McKesson Q3 2025 Earnings Analysis: Examining Revenue Growth, Strategic Acquisitions, and Future Outlook in the Pharmaceutical Industry
Mar 7, 2025

McKesson (MCK) Analysis: Q3 2025 Results, PRISM Acquisition

In-depth analysis of McKesson's Q3 2025 results, PRISM Vision acquisition, and market outlook. Key takeaways for investors and strategic implications.

Read more →
McKesson (MCK) Q3 2025 Earnings Analysis: Revenue growth, market trends, and future outlook for healthcare services and pharmaceutical distribution.
Mar 3, 2025

McKesson (MCK): Q3 2025 Earnings, Market Trends, and Future Outlook

McKesson Corporation (MCK) faces mixed Q3 2025 results, but strategic growth in pharmaceuticals and RxTS offers a promising outlook. Dividend declared.

Read more →
McKesson (MCK) Stock Analysis: Q3 Earnings, Oncology Strategy, and Future Growth Outlook
Feb 28, 2025

McKesson (MCK) Analysis: Q3 Earnings, Oncology Strategy, and Future Outlook

A comprehensive analysis of McKesson Corporation (MCK), including Q3 earnings, strategic initiatives, analyst estimates, and macroeconomic factors. A balanced outlook for investors.

Read more →
McKesson (MCK) Q3 2025 Earnings Analysis: Examining performance, challenges, and strategic opportunities in the healthcare landscape. Stay informed on MCK stock trends.
Feb 26, 2025

McKesson (MCK) Q3 2025 Earnings Analysis: Challenges and Opportunities

McKesson's Q3 2025 earnings reveal a mixed performance amid macroeconomic challenges. Strategic initiatives and investor sentiment shape the future outlook.

Read more →
McKesson Q3 2025 Earnings Analysis: Insights on MCK's Performance, Revenue, and Future Guidance.
Feb 25, 2025

McKesson (MCK) Q3 2025 Earnings: Revenue Misses, EPS Beats, and Revised Guidance

McKesson's Q3 Fiscal 2025 results present a mixed picture: EPS beats expectations, but revenue falls short, prompting a deeper look into strategic moves and market dynamics.

Read more →
McKesson Q3 2025 Earnings: Analysis of financial performance, challenges, and growth opportunities for investors.
Feb 24, 2025

McKesson (MCK) Q3 2025 Earnings: Challenges and Opportunities

McKesson's Q3 2025 reveals mixed performance with EPS beat but revenue miss. Focus shifts to strategic initiatives and market adaptation.

Read more →
McKesson Q3 2025 Analysis: Earnings beat, revenue miss, and strategic outlook.
Feb 21, 2025

McKesson Q3 2025: Earnings Beat Masks Revenue Concerns

McKesson’s Q3 2025 earnings surpassed EPS targets despite a revenue miss, highlighting segmented growth and evolving market challenges.

Read more →
McKesson Corporation Q3 2025 Performance Analysis: Strategic Outlook and Investor Considerations in the Healthcare Distribution Landscape. Learn about MCK's earnings, challenges, and future prospects.
Feb 21, 2025

McKesson Corporation Announces Major Business Developments | Latest Industry News

McKesson Corporation's latest news: Q3 earnings analysis, strategic shifts, and market impact. Stay informed with real-time data and expert insights.

Read more →